Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
pexelizumab · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| pexelizumab | DRUG | - |
INCLUSION CRITERIA: The study population will be drawn from patients undergoing CABG or CABG plus valve surgery using a bypass pump. In addition, they must meet all of the following criteria: * be at least 18 years of age; * have one or more of the following risk factors: * diabetes mellitus; * pr...
Pexelizumab is an investigational monoclonal antibody developed by AstraZeneca PLC. It was studied in patients undergoing coronary artery bypass graft surgery with cardio-pulmonary bypass, a cardiovascular procedure. It is a Phase 3 candidate and is not described as approved.
Pexelizumab was studied for use in patients undergoing coronary artery bypass graft surgery with cardio-pulmonary bypass. Its Phase 3 trial evaluated its effect on all-cause mortality and myocardial infarction in that surgical setting. It is an investigational agent, not a marketed therapy.
Pexelizumab targets C5, a complement protein, and acts as an inhibitor of that target. By binding C5, the monoclonal antibody is designed to block complement-mediated activity associated with cardio-pulmonary bypass. This mechanism was the basis for its study in cardiac surgery.
Pexelizumab is developed by AstraZeneca PLC, which trades under the ticker AZN. AstraZeneca sponsored the Phase 3 program evaluating the antibody in coronary artery bypass graft surgery with cardio-pulmonary bypass.
Pexelizumab is in Phase 3 development. Its single Phase 3 trial, NCT00048308, is completed, and no active trials are listed. The drug is investigational and has not been described as FDA approved for any indication.
Pexelizumab was evaluated in one Phase 3 trial, NCT00048308, titled Effect of Pexelizumab on All-Cause Mortality and Myocardial Infarction in Patients Undergoing Coronary Artery Bypass Graft Surgery With Cardio-Pulmonary Bypass. The completed trial enrolled 3,000 patients across the United States and Canada.